NASDAQ:OPRX OptimizeRx (OPRX) Stock Price, News & Analysis $6.64 +0.35 (+5.56%) Closing price 02/14/2025 04:00 PM EasternExtended Trading$6.39 -0.25 (-3.75%) As of 02/14/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About OptimizeRx Stock (NASDAQ:OPRX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get OptimizeRx alerts:Sign Up Key Stats Today's Range$6.24▼$6.6950-Day Range$4.75▼$6.6452-Week Range$3.78▼$16.65Volume190,388 shsAverage Volume120,694 shsMarket Capitalization$122.31 millionP/E RatioN/ADividend YieldN/APrice Target$9.06Consensus RatingModerate Buy Company OverviewOptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events. The company was founded in 2006 and is based in Waltham, Massachusetts.Read More… OptimizeRx Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreOPRX MarketRank™: OptimizeRx scored higher than 68% of companies evaluated by MarketBeat, and ranked 283rd out of 657 stocks in the computer and technology sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingOptimizeRx has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 6 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageOptimizeRx has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about OptimizeRx's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for OptimizeRx are expected to grow in the coming year, from ($0.33) to ($0.29) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of OptimizeRx is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of OptimizeRx is -4.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOptimizeRx has a P/B Ratio of 0.95. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about OptimizeRx's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.14% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.92%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldOptimizeRx does not currently pay a dividend.Dividend GrowthOptimizeRx does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.14% of the float of OptimizeRx has been sold short.Short Interest Ratio / Days to CoverOptimizeRx has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in OptimizeRx has recently increased by 4.92%, indicating that investor sentiment is decreasing. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for OptimizeRx this week, compared to 2 articles on an average week.Search Interest3 people have searched for OPRX on MarketBeat in the last 30 days. MarketBeat Follows2 people have added OptimizeRx to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, OptimizeRx insiders have bought more of their company's stock than they have sold. Specifically, they have bought $100,200.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 6.10% of the stock of OptimizeRx is held by insiders.Percentage Held by Institutions76.47% of the stock of OptimizeRx is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about OptimizeRx's insider trading history. Receive OPRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for OptimizeRx and its competitors with MarketBeat's FREE daily newsletter. Email Address OPRX Stock News HeadlinesOne OptimizeRx Insider Raised Their Stake In The Previous YearFebruary 12, 2025 | uk.finance.yahoo.comOptimizeRX edges higher as holder pushes firm to explore a saleFebruary 6, 2025 | msn.com81 Nations Meet to Overthrow USDSecret BRICS “DeDollarization” Meeting Leaked… Putin has gone as far as calling the USD a "weapon" (and he's not alone!). February 17, 2025 | True Gold Republic (Ad)Strong week for OptimizeRx (NASDAQ:OPRX) shareholders doesn't alleviate pain of three-year lossJanuary 24, 2025 | finance.yahoo.comOptimizeRx (OPRX) was downgraded to a Hold Rating at Stifel NicolausJanuary 13, 2025 | markets.businessinsider.comOptimizeRx downgraded to Sector Perform from Outperform at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx (OPRX) was downgraded to a Hold Rating at RBC CapitalJanuary 8, 2025 | markets.businessinsider.comOptimizeRx downgraded to "sector perform" by RBC amid slower growth outlookJanuary 8, 2025 | msn.comSee More Headlines OPRX Stock Analysis - Frequently Asked Questions How have OPRX shares performed this year? OptimizeRx's stock was trading at $4.86 on January 1st, 2025. Since then, OPRX stock has increased by 36.6% and is now trading at $6.64. View the best growth stocks for 2025 here. How were OptimizeRx's earnings last quarter? OptimizeRx Co. (NASDAQ:OPRX) released its quarterly earnings results on Tuesday, May, 14th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.16. The firm had revenue of $19.69 million for the quarter, compared to the consensus estimate of $18.66 million. OptimizeRx had a negative trailing twelve-month return on equity of 4.92% and a negative net margin of 27.41%. Who are OptimizeRx's major shareholders? OptimizeRx's top institutional investors include Whetstone Capital Advisors LLC (7.33%), Royce & Associates LP (5.81%), Blair William & Co. IL (3.26%) and Kennedy Capital Management LLC (3.22%). Insiders that own company stock include William J Febbo, James Paul Lang, Marion Odence-Ford, Stephen L Silvestro, Edward Stelmakh and Ellen O'connor Vos. View institutional ownership trends. How do I buy shares of OptimizeRx? Shares of OPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of OptimizeRx own? Based on aggregate information from My MarketBeat watchlists, some other companies that OptimizeRx investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings5/14/2024Today2/17/2025Next Earnings (Estimated)4/15/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorComputer and Technology Industry Business services, not elsewhere classified Sub-IndustryBusiness Services Current SymbolNASDAQ:OPRX CUSIPN/A CIK1448431 Webwww.optimizerx.com Phone(248) 651-6568Fax248-453-5529Employees100Year FoundedN/APrice Target and Rating Average Stock Price Target$9.06 High Stock Price Target$16.00 Low Stock Price Target$5.00 Potential Upside/Downside+36.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-17,570,000.00 Net Margins-27.41% Pretax Margin-37.84% Return on Equity-4.92% Return on Assets-3.41% Debt Debt-to-Equity Ratio0.29 Current Ratio3.23 Quick Ratio3.23 Sales & Book Value Annual Sales$71.52 million Price / Sales1.71 Cash FlowN/A Price / Cash FlowN/A Book Value$6.97 per share Price / Book0.95Miscellaneous Outstanding Shares18,420,000Free Float17,297,000Market Cap$122.31 million OptionableOptionable Beta1.38 Social Links 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:OPRX) was last updated on 2/17/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredHe called the top and bottom of Bitcoin nearly to the day … Here’s what he says is next.With Donald Trump’s return to the oval office, the war on crypto is over. The digital currency is not only ...Weiss Ratings | SponsoredAmerica cannot power AIThere’s a fatal flaw at the heart of the AI revolution… With AI continuing to explode in popularity, tech c...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OptimizeRx Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share OptimizeRx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.